Rapport Therapeutics (NASDAQ:RAPP) Stock Jumps 7.5% on Insider Buying Activity

Rapport Therapeutics, Inc. (NASDAQ:RAPP)’s stock price traded up 7.5% on Thursday following insider buying activity. The company traded as high as $26.98 and last traded at $26.9330. Approximately 111,919 shares were traded during mid-day trading, a decline of 72% from the average session volume of 400,062 shares. The stock had previously closed at $25.06.

Specifically, CFO Troy Ignelzi bought 5,500 shares of Rapport Therapeutics stock in a transaction on Wednesday, October 21st. The stock was acquired at an average cost of $26.10 per share, for a total transaction of $143,550.00. Following the completion of the acquisition, the chief financial officer owned 15,500 shares of the company’s stock, valued at $404,550. This trade represents a 55.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Analyst Ratings Changes

Several analysts have recently commented on RAPP shares. Guggenheim increased their price objective on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. Raymond James Financial restated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research report on Tuesday. Wall Street Zen cut Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Leerink Partners assumed coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Rapport Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $68.36.

More Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 advanced toward Phase 3. Rapport reported that RAP-219 met both Phase 2 endpoints in bipolar mania, showing statistically significant placebo-adjusted improvements in manic symptoms. The company plans to begin Phase 3 development, potentially increasing the program’s value and expanding its addressable market. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts raised or maintained bullish price targets. JonesTrading increased its target from $50 to $82, while Raymond James raised its target to $86. BTIG also increased its target, and HC Wainwright reaffirmed a Buy rating with a $66 target. The revisions reflect expectations that RAP-219 could become a significant commercial opportunity, with potential peak sales estimates near $1 billion. BTIG raises Rapport price target
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares at an average price of $26.10, investing $143,550 and increasing his direct ownership by 55%. The open-market purchase may be viewed as a signal of management confidence in the company’s outlook. Rapport CFO stock purchase
• Neutral Sentiment: The Phase 2 results support further development but do not eliminate clinical, regulatory, financing, or commercialization risks. RAP-219 is still an experimental therapy, and Phase 3 trials will require additional time and capital.
• Negative Sentiment: Some reports characterized the bipolar-mania results as a narrow win relative to initial expectations. Rapport also remains unprofitable and previously reported quarterly EPS below consensus, which could limit upside if development costs rise or future data disappoint. Rapport bipolar data analysis

Rapport Therapeutics Trading Up 10.4%

The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -9.09 and a beta of 1.22. The company has a fifty day moving average price of $39.86 and a 200-day moving average price of $39.07.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, research analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently bought and sold shares of the company. TRV GP V LLC acquired a new position in Rapport Therapeutics in the 2nd quarter valued at $261,709,477. ARCH Venture Management LLC purchased a new position in Rapport Therapeutics in the 2nd quarter valued at $155,376,512. BlackRock Inc. purchased a new position in Rapport Therapeutics in the 2nd quarter valued at $112,500,000. Johnson & Johnson acquired a new stake in Rapport Therapeutics during the 2nd quarter worth $74,360,823. Finally, TRV GP VI LLC acquired a new stake in Rapport Therapeutics during the 2nd quarter worth $40,387,314.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.